Progyny, Inc., a benefits management company, specializes in fertility benefits and family development solutions for employers in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.29B |
| Gross Profit (TTM) | $311.76M |
| EBITDA | $109.51M |
| Operating Margin | 10.80% |
| Return on Equity | 14.90% |
| Return on Assets | 9.12% |
| Revenue/Share (TTM) | $15.30 |
| Book Value | $5.66 |
| Price-to-Book | 5.63 |
| Price-to-Sales (TTM) | 1.86 |
| EV/Revenue | 1.758 |
| EV/EBITDA | 22.33 |
| Quarterly Earnings Growth (YoY) | 70.60% |
| Quarterly Revenue Growth (YoY) | 1.40% |
| Shares Outstanding | $78.33M |
| Float | $71.66M |
| % Insiders | 1.95% |
| % Institutions | 112.26% |
Volatility is currently contracting
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.
JBHT, PGNY, BSET, VSXY and PARR stand out for relative price strength, positive estimate revisions and solid fundamentals amid market uncertainty.
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Progyny (PGNY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Progyny (PGNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Progyny, Inc. (PGNY) Shareholder/Analyst Call Transcript
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PGNY and any ticker you trade — then tracks every position and per-strategy win rate.
